Abstract
Wnt signaling regulates a multitude of critical processes in development and tissue homeostasis. The wingless (wg) gene product was first identified in Drosophila in 1973. Subsequently, the proto-oncogene INT-1 was identified in mice in 1984 when its activation by mouse mammary tumor virus proviral insertion was found to induce tumor formation. The discovery in 1987 that wg and INT-1 are orthologues contributed to an appreciation of the intimate connection between oncogenic and developmental processes. Diverse diseases including cancer, diabetes, osteoporosis and psychiatric disorders may be amenable to treatment via modulation of Wnt-mediated signaling pathways. There are a number of attractive targets that are the object of ongoing drug development studies aiming to capitalize on these opportunities. In this review, we present a historical overview of key events in this field that have elucidated the known signaling cascades associated with Wnt ligands and shaped our understanding of the roles of these cascades in physiological and pathological processes.
Current Drug Targets
Title: Wnt Signaling in Development, Disease and Translational Medicine
Volume: 9 Issue: 7
Author(s): Gary S. Coombs, Tracy M. Covey and David M. Virshup
Affiliation:
Abstract: Wnt signaling regulates a multitude of critical processes in development and tissue homeostasis. The wingless (wg) gene product was first identified in Drosophila in 1973. Subsequently, the proto-oncogene INT-1 was identified in mice in 1984 when its activation by mouse mammary tumor virus proviral insertion was found to induce tumor formation. The discovery in 1987 that wg and INT-1 are orthologues contributed to an appreciation of the intimate connection between oncogenic and developmental processes. Diverse diseases including cancer, diabetes, osteoporosis and psychiatric disorders may be amenable to treatment via modulation of Wnt-mediated signaling pathways. There are a number of attractive targets that are the object of ongoing drug development studies aiming to capitalize on these opportunities. In this review, we present a historical overview of key events in this field that have elucidated the known signaling cascades associated with Wnt ligands and shaped our understanding of the roles of these cascades in physiological and pathological processes.
Export Options
About this article
Cite this article as:
Coombs S. Gary, Covey M. Tracy and Virshup M. David, Wnt Signaling in Development, Disease and Translational Medicine, Current Drug Targets 2008; 9 (7) . https://dx.doi.org/10.2174/138945008784911796
DOI https://dx.doi.org/10.2174/138945008784911796 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease
Current Molecular Medicine Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor
Current Cancer Drug Targets Amyloidogenicity of p53: A Hidden Link Between Protein Misfolding and Cancer
Current Protein & Peptide Science Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Anesthesia for Bronchoscopy
Current Pharmaceutical Design Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology Nanoparticles based on oleate alginate ester as curcumin delivery system
Current Drug Delivery The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Dendrimer-Based Contrast Agents for Molecular Imaging
Current Topics in Medicinal Chemistry A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology MicroRNA-203: Tumor Suppression and Beyond
MicroRNA